Shares of drug firm Granules India today soared nearly 7 per cent after the company's subsidiary received approval from the US health regulator for Methylergonovine tablets, used for prevention and control of postpartum haemorrhage.
The scrip advanced by 6.61 per cent to end at Rs 103.15
on BSE. Intra-day, it zoomed 10.18 per cent to Rs 106.60.
On NSE, shares of the company surged 6.67 per cent to close at Rs 103.15.
On the equity volume front, 8.75 lakh shares of the company were traded on BSE and over one crore shares changed hands on NSE during the day.
In a filing to the BSE, Granules India said, "the U S Food and Drug Administration (US FDA) has approved its abbreviated new drug applications (ANDA) for Methylergonovine 0.2 mg tablets. The ANDA was filed by Granules Pharmaceuticals Inc, a wholly owned subsidiary of Granules India Ltd".
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)